RU2003133446A - Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения - Google Patents

Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения Download PDF

Info

Publication number
RU2003133446A
RU2003133446A RU2003133446/15A RU2003133446A RU2003133446A RU 2003133446 A RU2003133446 A RU 2003133446A RU 2003133446/15 A RU2003133446/15 A RU 2003133446/15A RU 2003133446 A RU2003133446 A RU 2003133446A RU 2003133446 A RU2003133446 A RU 2003133446A
Authority
RU
Russia
Prior art keywords
carvedilol
hours
released
pharmaceutical composition
oral pharmaceutical
Prior art date
Application number
RU2003133446/15A
Other languages
English (en)
Russian (ru)
Inventor
Дилип Шантилал ШАНГХВИ (IN)
Дилип Шантилал ШАНГХВИ
Бала Рамеша Р. ЧАРИ (IN)
Бала Рамеша Р. ЧАРИ
Зиауддин З. ТЬЕБДЖИ (IN)
Зиауддин З. ТЬЕБДЖИ
Original Assignee
Сан Фармасьютикал Индастриз Лимитид (In)
Сан Фармасьютикал Индастриз Лимитид
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фармасьютикал Индастриз Лимитид (In), Сан Фармасьютикал Индастриз Лимитид filed Critical Сан Фармасьютикал Индастриз Лимитид (In)
Publication of RU2003133446A publication Critical patent/RU2003133446A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
RU2003133446/15A 2001-05-17 2002-05-10 Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения RU2003133446A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-17 2001-05-17
IN464/MUM/2001 2001-09-03

Publications (1)

Publication Number Publication Date
RU2003133446A true RU2003133446A (ru) 2005-03-10

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003133446/15A RU2003133446A (ru) 2001-05-17 2002-05-10 Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения

Country Status (16)

Country Link
US (1) US20030035836A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1395258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2004534031A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20040037026A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1525855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002314515B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1014328A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0210976A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2447005A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0400607A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03010501A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL370589A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2003133446A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002092078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200309724B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69917618T2 (de) 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
WO2004002472A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
US7268156B2 (en) * 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
DE602004014747D1 (de) 2003-03-26 2008-08-14 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
ES2401769T5 (es) * 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
CA2674536C (en) * 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
TWI494108B (zh) * 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
ES2600894T3 (es) * 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
ES2706994T3 (es) 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2285407C (en) * 1997-03-11 2006-08-01 Darwin Discovery Limited Dosage forms comprising separate portions of r- and s-enantiomers
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1233768A1 (en) * 1999-11-15 2002-08-28 Smithkline Beecham Carvedilol methanesulfonate
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS

Also Published As

Publication number Publication date
CA2447005A1 (en) 2002-11-21
IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-09-13
AU2002314515B2 (en) 2007-08-16
KR20040037026A (ko) 2004-05-04
JP2004534031A (ja) 2004-11-11
MXPA03010501A (es) 2004-03-02
PL370589A1 (en) 2005-05-30
CN1525855A (zh) 2004-09-01
HUP0400607A2 (hu) 2004-07-28
ZA200309724B (en) 2005-05-25
BR0210976A (pt) 2004-10-05
US20030035836A1 (en) 2003-02-20
BE1014328A7 (fr) 2003-08-05
HUP0400607A3 (en) 2005-07-28
EP1395258A1 (en) 2004-03-10
WO2002092078A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
RU2003133446A (ru) Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения
US4784858A (en) Controlled release tablet
JPH02209A (ja) カルビドパ/レボドパの制御放出配合剤
CA2675724A1 (en) Oral extended-release composition
EP2405900A2 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
CN112891546A (zh) 单独的或与降解分子组合的吸附剂的位置特异性肠内递送
BRPI9802144B1 (pt) dispositivo osmótico multicapa aperfeiçoado
KR20080028361A (ko) 퀴닌-함유 제어-방출형 제제
NO301578B1 (no) Legemiddelfrigjörelseregulerende beleggmateriale for farmasöytiske preparater med langvarig virkning, og anvendelse derav
CA2304135C (en) Medicament formulation with a controlled release of an active agent
WO2013000578A1 (en) Controlled release oral dosage form comprising oxycodone
EP3609472A1 (en) Extended release compositions comprising pyridostigmine
BG107372A (bg) Препарати със забавено действие на хинолонови антибиотици и метод за получаването им
JP2005526739A (ja) コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤
WO2004016249A1 (en) Extended release matrix tablets
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
KR20140121394A (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
DE60319983T2 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
EP1539113A2 (en) Modified release ketoprofen dosage form
WO2005011666A1 (en) Stable sustained release oral dosage form of gabapentin
US20070112075A1 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
US9561241B1 (en) Gastroretentive dosage forms for minocycline
RU2152212C1 (ru) Лекарственная форма производных 5-нитроимидазола
US6129931A (en) Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone